Reply  by Sorajja, Paul & Ommen, Steve R
2. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase
inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in
central nervous system autoimmune disease. Nature 2002;420:78–84.
Myocardial Bridging in Adult and Pediatric
Patients With Hypertrophic Cardiomyopathy
Is Not Associated With Poor Outcome
The recent report by Sorajja et al. (1) that myocardial bridging in
adults with hypertrophic cardiomyopathy (HCM) is not associated
with an increased risk of sudden death is in agreement with our
own study conducted in children (2), and is in contrast to the
suggestion that systolic coronary compression in pediatric patients
results in myocardial ischemia and a poor prognosis (3).
Unfortunately, Sorajja et al. (1) misrepresent our findings. They
include our study with references that have associated myocardial
bridging with “nuclear perfusion abnormalities, chest pain, ven-
tricular tachycardia and an increased risk of sudden cardiac death.”
Our conclusions were directly the opposite: we found no associa-
tion between coronary bridging, symptoms, perfusion abnormali-
ties, ventricular arrhythmias, and sudden death. Rather, in multi-
variate analyses, perfusion abnormalities were related to the
magnitude of left ventricular hypertrophy (LVH) and the presence
of septal artery compression. Unfortunately, Sorajja et al. did not
evaluate angiograms for septal artery compression, and the associ-
ation between bridging and severity of LVH is not assessed in
patient groups of similar age. Finally, our study was conducted in
a group of 57 pediatric patients, and not in only 23 as stated in the
current report.
The report by Sorajja et al. emphasizes our conclusions that it is
very unlikely that systolic compression of epicardial coronary
arteries results in poorer outcome in HCM, and that there is
currently no rationale for surgical or catheter-based correction (2).
The contribution made by septal artery compression, intraventric-
ular pressure, and LVH to perfusion abnormalities and therefore to
symptoms and prognosis should be the focus of further investiga-
tion.
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REPLY
We appreciate the interest of Drs. Mohiddin and Fananapazir in
our recent publication on myocardial bridging in adult patients
with hypertrophic cardiomyopathy (HCM) (1). We apologize for
any misrepresentation of the data from their publication on
myocardial bridging in pediatric patients with HCM (2). The
study published by Mohiddin et al. was included in the list of
references that associated bridging with perfusion abnormalities, as
their study had demonstrated such an association in univariate
analyses. We emphasized the absence of this relation, in their
study, after adjustment for other clinical variables in order to
support our conclusions that bridging is not associated with an
adverse prognosis.
Septal artery compression was not examined in our study.
However, it is unlikely that this finding would be associated with
adverse outcomes as such compression is found in nearly all
patients with epicardial bridging, and there were no differences
with respect to ventricular tachycardia or prognosis in the inves-
tigators’ study (2). We observed no difference in maximal left
ventricular wall thickness between patients with and without
bridging. Finally, the study by Drs. Mohiddin and Fananapazir did
examine 57 pediatric HCM patients, of whom 23 had myocardial
bridging. We apologize for this typographical error.
Paul Sorajja, MD
Steve R. Ommen, MD
Division of Cardiovascular Disease and Internal Medicine
Mayo Clinic
200 1st St. SW
Rochester, MN 55905
E-mail: ommen.steve@mayo.edu
doi:10.1016/j.jacc.2003.12.032
REFERENCES
1. Sorajja P, Ommen SR, Nishimura RA, et al. Myocardial bridging in
adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
2003;42:889–94.
2. Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging
does not predict sudden death in children with hypertrophic cardiomy-
opathy but is associated with more severe cardiac disease. J Am Coll
Cardiol 2000;36:2270–8.
Embolic Complications in
Streptococcus Viridans Endocarditis
In their editorial, entitled “Toward reducing embolic complica-
tions from endocarditis,” Drs. Homma and Grahame-Clarke
indicated that the type of the organism may increase the likelihood
of embolization and that Streptococcus viridans and Staphylococcus
aureus endocarditis are associated with higher incidence of embo-
lization (1). Though this is correct for S. aureus endocarditis, S.
viridans endocarditis is not specifically associated with higher
incidence of embolization (2,3). McLeod et al. (2), Cherubin et al.
(3), and Utley et al. (4,5) found the highest incidence of emboli
with fungus infection (60% to 100%), S. aureus (58%), and
Neisseria (35%). Streptococcus species, including viridans, and
enterococci had a lower risk of embolization (15% to 25%). In their
editorial, Homma and Grahame-Clarke quoted De Castro et al.
for higher embolization in S. viridans (6). However, De Castro et
al. showed in their series that only 6 out of 22 patients with
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